GlassScriptPhysician profile
John Floyd Robinson
NPI 1952833097
$2,935.29
in general payments reported to CMS, 2019-2025
15 companies · $42.63 in 2025
The $42.63 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2021: $555 · 2022: $1,121 · 2023: $724 · 2024: $388 · 2025: $42.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,216.99 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $233.61 | 2021-2022 | |
| Allergan, INC. | $216.85 | 2022 | |
| Janssen Scientific Affairs, LLC | $152.81 | 2022 | |
| Horizon Therapeutics Plc | $149.48 | 2021 | |
| Abbott Laboratories | $136.35 | 2023 | Infinity |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2022 | |
| Lundbeck LLC | $124.99 | 2023 | Vyepti |
| Kyowa Kirin, INC. | $122.53 | 2022 | |
| Alnylam Pharmaceuticals INC. | $121.36 | 2023 | Amvuttra |
| Pfizer INC. | $105.64 | 2019 | |
| Alexion Pharmaceuticals, INC. | $95.57 | 2022 | |
| Janssen Pharmaceuticals, INC | $81.14 | 2022 | |
| Biogen, INC. | $34.63 | 2021 | |
| Sk Life Science, INC. | $18.34 | 2023 | Xcopri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.